Alvotech ALVO

$6.11 +0.66 (12.11%)

Valuation

Market cap
1,644,843,000
Revenue TTM
$586,320,000
Net income TTM
$27,920,000
PE ratio
0.00
Forward PE
890.18
Profit margin
4.76%
Debt to equity
-6.82

Trading

Volume
2,898,800
Avg volume
1,144,932
Day's range
$5.90 – $6.53
Shares out
301,806,000
Stochastic %K
62%
Beta
0.20
Analysts
Strong Sell
Price target
$6.80

Price

Company profile

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis,...

Show more

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Website
https://www.alvotech.com
Address
9, Rue de Bitbourg, Luxembourg, Luxembourg

Latest news

Stocktwits

Armin1971 Oct 6, 4:47 AM
$ALVO its a ten bagger stock..biosimilar we need all over the world...
0 replies
KryptonResearch14 Oct 5, 11:07 PM
$ALVO Alvotech got a manufacturing unlock from the FDA this morning: the agency approved a BLA supplement letting the company make SIMLANDI, its Humira biosimilar, in a second drug-substance suite at its Reykjavik plant. The company says it effectively doubles the drug-substance capacity available for US supply. In the Humira biosimilar price war, the constraint is supply, not demand. That is the first-order read. The second-order read is the facility itself. The FDA closed its most recent Reykjavik inspection with a VAI (Voluntary Action Indicated) classification in July, and Alvotech expects the agency can now act on other pending applications tied to the site. That inspection history was the gating item. Shares rose about 13 percent on the day. The stock is still roughly 26 percent below where it traded a year ago.
0 replies
Kosmokrat Oct 5, 6:38 PM
Nice news today, and even nicer jump in SP. I will for sure hold for a bit longer. I wonder where the SP is when the FDA approval for AVT03, AVT05, and AVT06 comes in. I hope it will go to $8+. But even then, I might not sell. What will 2027 bring? What revenue and EPS can $ALVO achieve in 2027? And will the launch of AVT16 / AVT80 also happen in 2027? Why not double digit in 2027?
0 replies
TrendIsMyFriend Oct 5, 6:37 PM
$ALVO See the trend here? 😎📈🔥👍
0 replies
Armin1971 Oct 5, 4:42 PM
$ALVO That the game changer the FDA
0 replies
TopTierNewswire Oct 5, 3:39 PM
$ALVO - great news catch from the AI model on Top Tier Newswire, up over 10% since being added as a top long candidate. "FDA approval doubles U.S. SIMLANDI capacity; stock up 13.85% on strong news."
0 replies
G101SPM Oct 5, 2:16 PM
$ALVO $6.34 bid Holding long position at profit BRIEF:Today announced that the U.S. Food and Drug Administration (FDA) has approved a supplement to the Biologics License Application (BLA) for AVT02 (adalimumab-ryvk), marketed in the U.S. as SIMLANDI®, enabling drug substance for the product to be manufactured in a second production suite at the company's Reykjavik facility. This approval further confirms resolution of inspection-related matters at the Reykjavik site. "This approval is important both operationally and as a further regulatory milestone for our Reykjavik facility," said Lisa Graver, Chief Executive Officer of Alvotech. "The addition of DSM2 effectively doubles the drug substance manufacturing capacity available to support U.S. supply and provides greater flexibility for commercial supply of AVT02 to the U.S. market. It also reflects the significant progress our teams have made in strengthening quality systems and manufacturing operations at the site." The second suite, DSM2, supports the complete drug substance manufacturing process, including cell culture and purification, and doubles Alvotech's manufacturing capacity available to support U.S. supply. DSM2 is already approved for the manufacture of commercial drug substance for European markets, including for AVT02, AVT03, and AVT05. Following the FDA approval, Alvotech can now manufacture AVT02 drug substance for U.S. commercial supply in either DSM1 or DSM2, providing additional capacity and greater flexibility across its manufacturing operations. The approval follows the FDA's July 2026 closure of its most recent
0 replies
TrendIsMyFriend Oct 5, 2:03 PM
$ALVO Consensus Price Target $8.50 33.73% Upside According to the 8 analysts' twelve-month price targets for Alvotech, the average price target is $8.50. The highest price target for ALVO is $10.00, while the lowest price target for ALVO is $7.00.
0 replies